Five-Year pill regimen tested to hold back silent lymphoma
NCT ID NCT03282396
Summary
This study is testing whether taking a daily pill called ibrutinib for up to five years can delay the progression of a slow-growing, high-risk form of mantle cell lymphoma in patients who have not yet received any treatment. The goal is to see if this long-term medication can keep the cancer from worsening and is safe for patients. Researchers will monitor participants closely to see how long they remain progression-free and how they respond to the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.